GAM
JAZZ icon

Generali Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Generali Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,473
Closed -$1.05M – 513
2025
Q1 		$1.05M Buy
8,473
+740
+10% +$96.5K 0.03% 382
2024
Q4 		$952K Buy
+7,733
New +$911K 0.02% 366

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Generali Asset Management's JAZZ Position: Q2 2025 in Review

Generali Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 8,473 shares — an estimated $1.05M sold.

Generali Asset Management first reported a position in JAZZ in Q4 2024 and held it in 2 quarters. The position peaked at $1.05M in Q1 2025. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

  • Generali Asset Management reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Generali Asset Management sold 8,473 Jazz Pharmaceuticals shares in Q2 2025, an estimated $1.05M.
  • Generali Asset Management first reported a position in Jazz Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Generali Asset Management's Jazz Pharmaceuticals position peaked at $1.05M in Q1 2025.
  • 501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on Generali Asset Management's 13F filing for Q2 2025, filed 28 Jul 2025.